Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2026)
Enanta Pharmaceuticals posted quarterly Gains from Sales and Divestitures of $148000.0 for Q1 2026, up 117.65% year-on-year from $68000.0 in Q1 2025, and up 117.65% on a QoQ basis from $68000.0 in Q1 2025.
Enanta Pharmaceuticals (ENTA) has 10 years of Gains from Sales and Divestitures data on file, last reported at $148000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 117.65% year-over-year to $148000.0; the trailing twelve-month figure through Mar 2026 stood at $148000.0 (up 117.65% YoY), and the FY2023 full-year result was $70000.0, up 1300.0% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $148000.0, up from $68000.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $148000.0 in Q1 2026 and bottomed at $5000.0 in Q3 2022.
- The 5-year median for Gains from Sales and Divestitures is $69000.0 (2023), against an average of $75583.3.
- The widest annual swing landed in 2022, when Gains from Sales and Divestitures sank 88.89%; it then surged 1300.0% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $56000.0 in 2022, then grew by 25.0% to $70000.0 in 2023, then soared by 105.71% to $144000.0 in 2024, then tumbled by 52.78% to $68000.0 in 2025, then jumped by 117.65% to $148000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $148000.0 (Q1 2026), $68000.0 (Q1 2025), and $144000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148,000.00 |
| Mar 31, 2026 | 148,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Jun 30, 2024 | 116,000.00 |
| Jun 30, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Mar 31, 2023 | 56,000.00 |
| Mar 31, 2023 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 29,000.00 |
| Jun 30, 2022 | 29,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Dec 31, 2021 | 29,000.00 |
| Dec 31, 2021 | 29,000.00 |
| Sep 30, 2021 | 45,000.00 |
| Sep 30, 2021 | 45,000.00 |
| Jun 30, 2021 | 45,000.00 |
| Jun 30, 2021 | 45,000.00 |
| Mar 31, 2021 | 45,000.00 |
| Mar 31, 2021 | 45,000.00 |
| Dec 31, 2020 | 45,000.00 |
| Dec 31, 2020 | 45,000.00 |
| Sep 30, 2020 | 48,000.00 |
| Sep 30, 2020 | 48,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 20,000.00 |
| Mar 31, 2020 | 20,000.00 |
| Dec 31, 2019 | 48,000.00 |
| Dec 31, 2019 | 48,000.00 |
| Sep 30, 2019 | 36,000.00 |
| Sep 30, 2019 | 36,000.00 |
| Mar 31, 2019 | 36,000.00 |
| Mar 31, 2019 | 36,000.00 |
| Sep 30, 2018 | 20,000.00 |
| Sep 30, 2018 | 20,000.00 |
| Jun 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 25,000.00 |
| Mar 31, 2018 | 25,000.00 |
| Mar 31, 2018 | 25,000.00 |
| Sep 30, 2017 | 19,000.00 |
| Sep 30, 2017 | 19,000.00 |
| Jun 30, 2017 | 18,820.00 |
| Jun 30, 2017 | 18,820.00 |